Alkem Laboratories reported 30.11% higher net profits at Rs.249 crore for Mar-21 quarter. Revenues from operations were up 6.98% at Rs.2,192 crore. India sales were up 17% while foreign sales were more up by around 8.5% yoy. Alkem had an annual R&D outlay at 6% of sales and a 400 bps rise in operating margins at 40% for FY21. R&D share of sales is at par with leading pharma companies in India.
Alkem Laboratories reported 30.11% higher net profits at Rs.249 crore for Mar-21 quarter. Revenues from operations were up 6.98% at Rs.2,192 crore. India sales were up 17% while foreign sales were more up by around 8.5% yoy. Alkem had an annual R&D outlay at 6% of sales and a 400 bps rise in operating margins at 40% for FY21. R&D share of sales is at par with leading pharma companies in India.